Vaccine Revac B-260 (530) at Dr. Essa Lab

Vaccine Revac B-260 (530) at Dr. Essa Lab

The Vaccine Revac B-260 (530) at Dr. Essa Lab represents a cornerstone of preventive medicine, specifically designed to provide active immunization against the Hepatitis B virus (HBV). Hepatitis B is a highly infectious viral pathogen that attacks the liver, potentially leading to acute illness, chronic hepatitis, progressive liver cirrhosis, and hepatocellular carcinoma (primary liver cancer). In Pakistan, where the burden of viral hepatitis remains a significant public health challenge, timely and effective immunization is paramount. Dr. Essa Laboratory & Diagnostic Centre, a pioneer in diagnostic and preventive healthcare since 1987, offers this high-quality recombinant vaccine to safeguard individuals, families, and healthcare workers from this preventable disease.

The Vaccine Revac B-260 (530) is formulated using advanced recombinant DNA technology. Instead of utilizing live or weakened viral particles, the vaccine is manufactured by inserting the gene code for the Hepatitis B surface antigen (HBsAg) into the yeast Saccharomyces cerevisiae. The yeast cells then produce the highly purified HBsAg proteins, which are harvested, purified, and adsorbed onto aluminum hydroxide to enhance their immunogenicity. When administered, this non-infectious antigen stimulates the host immune system to produce specific neutralizing antibodies (anti-HBs). These antibodies remain in the immunological memory, ready to neutralize the actual virus if exposure occurs in the future. Because it contains no viral DNA or live components, the vaccine cannot transmit Hepatitis B or any other infectious agent, making it exceptionally safe for all age groups.

The clinical importance of receiving the Vaccine Revac B-260 (530) at Dr. Essa Lab cannot be overstated. Hepatitis B is transmitted through contact with infectious blood or body fluids, which can occur via needle-stick injuries, unsafe injection practices, blood transfusions, sexual contact, or vertically from mother to child during childbirth. Because many individuals with chronic Hepatitis B remain asymptomatic for decades, vaccination serves as the primary shield against silent transmission. By establishing a robust immunological barrier, this vaccine protects not only the individual but also contributes to herd immunity, reducing the overall prevalence of HBV within the community of Karachi and beyond.

Clinical Procedure: What to Expect

Patient Preparation

To ensure maximum safety and efficacy, patients undergoing immunization with the Vaccine Revac B-260 (530) at Dr. Essa Lab should follow these preparation guidelines:

• Medical History Review: Inform the healthcare provider of any known allergies, particularly to yeast or any vaccine components, as well as previous adverse reactions to vaccinations.
• Current Health Status: If you are experiencing a moderate to severe acute illness accompanied by a high-grade fever, it is advisable to defer the vaccination until recovery. Mild illnesses, such as a common cold or low-grade fever, are generally not contraindications.
• Medication Disclosure: Disclose all current medications, especially immunosuppressive therapies, chemotherapy, or systemic corticosteroids, as these may reduce the vaccine's immunogenic effectiveness.
• Pregnancy and Lactation: Inform the clinical staff if you are pregnant, planning to become pregnant, or breastfeeding. While recombinant vaccines are generally considered safe, a clinical evaluation is recommended.
• No Fasting Required: There is no need to fast before receiving the vaccine. Eating a light meal and staying hydrated can prevent dizziness or vasovagal episodes during the injection.
• Clothing Choice: Wear loose-fitting clothing that allows easy access to the deltoid muscle of the upper arm, which is the preferred site for adult administration.

During the Procedure

The administration of the Vaccine Revac B-260 (530) at Dr. Essa Lab is conducted in a sterile, highly controlled clinical environment by trained nursing professionals. The procedure involves the following steps:

• Patient Identification and Verification: The clinical staff will verify your identity, check the prescription, and confirm the specific vaccine dose and batch number.
• Positioning: The patient is comfortably seated. The injection site, typically the deltoid muscle of the non-dominant upper arm (or the anterolateral aspect of the thigh in infants), is exposed.
• Aseptic Preparation: The healthcare professional cleanses the skin at the injection site with an alcohol swab using a circular motion and allows it to air dry completely.
• Injection Technique: The vaccine is administered via an intramuscular (IM) injection. The clinician inserts the needle at a 90-degree angle to ensure the vaccine is deposited deep into the muscle tissue, which optimizes absorption and reduces local irritation.
• Duration: The actual injection takes only a few seconds. The patient may feel a brief, mild pinching sensation as the needle enters and a slight pressure as the suspension is introduced.
• Post-Injection Care: A sterile cotton ball or adhesive bandage is applied to the site with gentle pressure. Patients are advised to remain seated in the waiting area for 15 to 20 minutes post-vaccination to monitor for any immediate allergic reactions or vasovagal syncope (fainting).

When is a Vaccine Revac B-260 (530) Performed?

Prevention of Hepatitis B Virus Infection

The primary indication for administering the Vaccine Revac B-260 (530) is to establish active, long-term immunity against the Hepatitis B virus. Physicians recommend this vaccine for infants, children, adolescents, and adults who have not been previously immunized. By completing the recommended multi-dose series, individuals develop protective antibody levels that prevent acute infection and the subsequent risk of chronic carrier status, which is a leading cause of liver failure and terminal hepatic malignancies.

Immunization for Healthcare Professionals

Healthcare workers, including doctors, nurses, laboratory technicians, and dental staff, are at a significantly elevated risk of occupational exposure to bloodborne pathogens. Accidental needle-stick injuries, mucosal splashes, and handling of clinical specimens expose these professionals to potential HBV transmission. Dr. Essa Lab provides the Vaccine Revac B-260 (530) as an essential occupational health measure to ensure that medical personnel are fully protected before entering clinical environments.

Protection for High-Risk Individuals

Certain patient populations exhibit a higher susceptibility to contracting Hepatitis B or developing severe complications if infected. This includes individuals undergoing hemodialysis for chronic kidney disease, patients requiring frequent blood transfusions (such as those with thalassemia or hemophilia), individuals with chronic liver diseases (like Hepatitis C or fatty liver), and those with immunocompromising conditions such as HIV. Immunization with this vaccine is a critical preventive strategy for these vulnerable groups.

Routine Vaccination Schedules

The vaccine is routinely administered as part of national immunization programs and pediatric schedules. It is typically given in a three-dose series (at 0, 1, and 6 months) to ensure robust, long-lasting immunological memory. Pediatricians and family physicians prescribe this specific formulation to ensure that children are protected from early childhood, a period when contracting HBV carries a 90% risk of progressing to chronic, life-threatening infection.

Travel Prophylaxis for Endemic Regions

International travelers visiting regions with high or intermediate prevalence rates of Hepatitis B (including parts of Asia, Africa, and South America) are strongly advised to receive the vaccine series. This is particularly important for travelers who may require medical treatment abroad, engage in adventure sports, or have prolonged contact with local populations, as it mitigates the risk of accidental exposure through local healthcare settings or close personal contact.

What Does a Vaccine Revac B-260 (530) Detect?

While the Vaccine Revac B-260 (530) is an immunizing agent rather than a diagnostic test, its administration triggers and evaluates several critical physiological and immunological parameters within the human body. Clinical monitoring and subsequent laboratory evaluations post-vaccination focus on the following aspects:

• Anti-HBs Antibody Seroconversion: Evaluates the body's ability to produce specific protective antibodies against the Hepatitis B surface antigen.
• Humoral Immune Response: Measures the activation of B-lymphocytes and their differentiation into antibody-secreting plasma cells.
• Immunological Memory Induction: Assesses the establishment of memory T and B cells that provide rapid, secondary immune responses upon future viral encounters.
• Seroprotection Threshold: Verifies if the anti-HBs antibody titer reaches the clinically protective level of ≥10 mIU/mL.
• Primary Vaccine Response: Determines the initial immune activation following the first dose of the vaccine series.
• Anamnestic Response: Evaluates the rapid booster effect and escalation of antibody levels following subsequent doses.
• Vaccine Safety Profile: Monitors for the absence of severe systemic adverse events, confirming the patient's tolerance to the recombinant formulation.
• Local Reactogenicity: Assesses mild, expected localized tissue responses such as transient erythema, warmth, or mild swelling at the injection site.
• Systemic Tolerability: Evaluates the body's general response, ensuring any systemic symptoms like low-grade fever or fatigue are mild and self-limiting.
• Cross-Protection Efficacy: Indirectly prevents Hepatitis D virus (HDV) infection, as HDV requires the presence of HBV to replicate and cause disease.
• Hepatocellular Integrity Protection: Ensures the long-term prevention of inflammatory hepatocyte destruction caused by viral replication.
• Prevention of Fibrogenesis: Evaluates the long-term clinical outcome of preventing chronic hepatic inflammation that leads to liver fibrosis.
• Absence of Active Infection: Confirms that the vaccine, being recombinant, does not introduce live viral particles, maintaining a negative HBsAg status post-administration.
• Immunological Competence: Serves as an indirect indicator of the patient's overall immune system functionality, particularly in immunocompromised individuals.
• Dose-Response Adequacy: Evaluates whether the standard dosing schedule is sufficient or if a high-dose regimen is required for specific patient cohorts.
• Long-term Antibody Persistence: Monitors the decay rate of anti-HBs antibodies over years to determine if booster doses are eventually required.
• Prevention of Vertical Transmission: Evaluates the protection of newborns when administered to high-risk mothers or immediately postpartum.
• Reduction in Community Viral Load: Contributes to epidemiological control by breaking the chain of transmission within the population.
• Prevention of Extrahepatic Manifestations: Protects against systemic immune-complex mediated complications associated with chronic HBV, such as polyarteritis nodosa or glomerulonephritis.
• Safety in Pediatric Populations: Confirms the high tolerability and safety margin of the recombinant formulation in infants and young children.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Laboratory & Diagnostic Centre, the administration of the Vaccine Revac B-260 (530) is documented immediately. Upon receiving the vaccine, patients are provided with an official, physical Immunization Card. This card details the vaccine name, batch number, manufacturer, date of administration, and the scheduled dates for subsequent doses. This documentation is crucial for school admissions, employment verification, and international travel requirements.

In addition to physical records, Dr. Essa Lab utilizes an advanced laboratory information management system (LIMS). Details of your vaccination are uploaded to your secure digital health profile. Patients can access their vaccination history and download digital copies of their immunization records through the official Dr. Essa Lab web portal or mobile application. For patients who undergo post-vaccination serology testing (Anti-HBs antibody titers) to verify immunity, the laboratory reports are typically available within 12 to 24 hours of sample collection, accessible online or via WhatsApp for maximum convenience.

Vaccine Revac B-260 (530) Findings Overview

The following table outlines the clinical parameters, expected normal responses, and potential abnormal findings evaluated during and after the administration of the Vaccine Revac B-260 (530):

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-HBs Antibody Titer	≥ 10 mIU/mL (Indicates protective immunity and successful seroconversion)	< 10 mIU/mL (Indicates non-response or insufficient immunological protection)
Hepatitis B Surface Antigen (HBsAg)	Negative (Confirms no active or chronic Hepatitis B infection)	Positive (Indicates pre-existing acute or chronic Hepatitis B infection)
Injection Site Reaction	No reaction, or mild, transient pain, redness, and swelling resolving within 48 hours	Severe local inflammation, persistent induration, sterile abscess, or secondary infection
Systemic Temperature	Normothermia (36.5°C to 37.5°C) or transient low-grade fever (< 38°C)	High-grade fever (> 38.5°C) or prolonged febrile state requiring medical evaluation
Immune System Response (Humoral)	Robust production of neutralizing IgG antibodies against HBsAg	Blunted or absent antibody response (commonly observed in immunocompromised patients)
Hypersensitivity Indicators	Absence of immediate allergic reactions (no urticaria, dyspnea, or anaphylaxis)	Immediate type I hypersensitivity reaction, bronchospasm, angioedema, or anaphylactic shock
Liver Function Enzymes (ALT/AST)	Normal baseline levels (indicating healthy, protected hepatocytes)	Elevated enzymes indicating pre-existing hepatic pathology or concurrent liver disease
Long-term Immunological Memory	Persistent memory B and T cell activation upon antigen re-exposure	Rapid decline in immunological memory or failure to establish long-term memory cells

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine Revac B-260 (530)?

• Experienced Healthcare Professionals: Our clinical and nursing staff are highly trained in aseptic injection techniques and pediatric immunization protocols.
• Strict Cold Chain Maintenance: Dr. Essa Lab ensures that all vaccines, including Revac B-260, are stored and transported under strict temperature-controlled conditions to preserve maximum potency.
• ISO Certified Standards: Operating under rigorous quality control systems, ensuring international standards of safety and clinical excellence.
• Patient-Focused Care: We prioritize patient comfort, offering a gentle, professional, and reassuring environment for both children and adults.
• Comprehensive Digital Records: Easy access to your immunization history and laboratory reports through our secure online portal and mobile app.
• Convenient Locations: With an extensive network of branches across Karachi and other cities, accessing quality vaccination services is highly convenient.
• Trusted Legacy: Serving the community since 1987, Dr. Essa Lab is a household name trusted for diagnostic accuracy and preventive healthcare.
• Post-Vaccination Support: We offer follow-up antibody testing (Anti-HBs titers) to clinically verify the development of protective immunity.